Viral Vector Manufacturing Market - Forecasts from 2022 to 2027

The global viral vector manufacturing market is projected to grow at a CAGR of 21.58% to reach a market size of US$1,866.670 million in 2027 from US$475.330 million in 2020.

The viral vector market is primarily driven by the growing adoption of adenoviral vectors, lentiviral vectors, and retroviral vectors. The growing adoption stems from the need for effectively transferring therapeutic genes into the target cells that are an integral part of the process that involves the insertion of a functional copy of a gene into a defective cell, one of the preferred treatment options for most chronic diseases, which is known as Gene therapy. The delivery of a genetic payload into a patient cell to produce a therapeutic effect, Viz. retargeting of an immune cell to fight cancer or mutated gene correction. This technique opens the possibilities of investing in haemophilia and cancer research thereafter achieving the cure of the disease with a single dose. Viral vectors have been utilized to treat a variety of diseases, that are inclusive of but not limited to cardiovascular diseases, different types of cancer, and hematologic, infectious as well as metabolic diseases. Furthermore, the growing number of clinical trials, the increasing number of gene therapies, and the expanding cognizance of effective modes of disease treatment are further expected to drive the growth of the viral vector manufacturing market during the forecast period. Because vector designing, production, packaging, and release testing are subject to limited availability and challenges due to the complex nature of technologies and platforms, many players in this space frequently seek strategic collaborations and acquisitions that cover many aspects, such as the delivery of clinal grade products, to facilitate the successful collaboration development of viral agent-based products.

Moreover, the efficient ability to express the therapeutic genes and their non-pathogenic nature is another factor that is responsible for driving the growth of this market. The other key factors that are expected to drive the growth of the market are the increasing investment in biopharmaceutical production coupled with the growing ageing population, healthcare expenditure, and technological advancement, especially in the genetic engineering segment. Moreover, the increasing accessibility of healthcare facilities and the growing demand for the treatment of diseases due to the increasing global burden of diseases are a few of the other factors that are poised to drive the growth of this market during the forecast period. Nevertheless, the transition of this niche industry to high manufacturing is one such factor that may restrain the growth of the market to a certain extent.

Therefore, with such a growing recognition of the importance of viral vectors, various developments are taking place in the viral vector manufacturing market. For instance, in June 2022, Avid Bioservices, Inc. inaugurated the analytical and process development suites in the company's new, viral vector development and Current Good Manufacturing Plant manufacturing facility. The set-up of the viral vector facility's CGMP manufacturing suites is still ongoing, with those capabilities expected to come online by mid-2023. In May 2022, AGC Biologics announced the addition of the viral vector suspension technology and capacity to aid the development and manufacturing of gene therapies at its commercial-grade campus located in Longmont, Colo. In October 2021, Catalent invested USD 230 million in order to increase the production of viral vectors at its gene therapy campus located in Harmans, Maryland. In September 2021, after building on the success of the Oxford-AstraZeneca vaccine against SARS-CoV-2, researchers from the University of Oxford and the Ludwig Institute for Cancer Research started on creating a vaccine to treat cancer. In November 2020, Vibalogivs, a global contract development and manufacturing organization, announced its plans of investing USD 150 million to set up a 110,000 square-foot facility near Boston in the United States. This facility would be used to produce commercial-stage and clinical oncolytic viruses and viral vectors. Further, in June 2020, it was announced by Emergent BioSolutions Inc. (NYSE: EBS), which is a global life sciences company, that it is going to invest $75 Million in Canton Site and expand its viral vector and gene therapy capabilities, facilitating the reinforcement of its contract development and manufacturing (CDMO) capabilities. Again, in June 2020, Oxford Biomedica (LSE: OXB), which is a major gene and cell therapy group, announced that it has signed an agreement of collaboration with the Vaccines Manufacturing and Innovation Centre (VMIC), a not-for-profit organization that has been established to provide the first strategic vaccine development and progressive manufacturing capability in the UK. Under this 5-year agreement, the organization will work towards enabling the manufacture of vaccines that are based on viral vectors, to contribute towards a swift growth in the domestic capacity for this specialized field of vaccine manufacturing. In April 2020, Merck KGaA (FWB: MRK), a leading science and technology company, announced that a € 100 million facility, second in Carlsbad, California USA that is intended to boost its BioReliance® viral and gene therapy service offering to help their customers to aid their customers to commercialize the gene therapies that are brought about by viral vectors concomitantly helping innovators scale up their production which is in tandem with the quantum that allows them to reach out to more patients. Earlier, in January 2020, the launch of ZYNTEGLO™ (autologous CD34+ cells encoding BA-T87Q-globin gene) in Germany was announced by bluebird bio, Inc. (Nasdaq: BLUE). ZYNTEGLO™ is a one-time gene therapy that has been specifically developed for patients aged 12 years and older with transfusion-dependent B-thalassemia (TDT) who do not possess the B0/B0 genotype. In December 2019, it was announced that a leading supplier of services and technologies for the life sciences industry called Novasep launched oXYgene™ which is a fully integrated offering for the construction of facilities dedicated towards customers to aid them in their viral vector production. In October 2019, it was reported that GE Healthcare Life Sciences, which has now rebranded itself as Cytiva, was about to launch the KUBio™ box, which is an adaptable, flexible, and fully integrated environment for biomanufacturing to accelerate the production of gene therapies based on viral vectors. These latest additions were intended to bring gene therapies swiftly to the market, thereby contributing to the increased capacity in the viral vector area. In March 2018, it was reported that Sartorius Stedim Biotech S.A. (SSB), which is a major international technology partner supplier of products and services to the biopharmaceutical industry, has been selected by ABL Europe as its chief supplier of single-use systems whereby the new viral vector manufacturing capacity has been started in Strasbourg at its European facility. ABL Europe, a subsidiary of ABL Inc., provides dedicated viral vector GMP manufacturing services for oncolytic, vaccine, and gene therapy projects in all stages of clinical development through commercial launch.

COVID-19 Insights

The COVID-19 pandemic highlighted the importance of vaccine development across the globe, and thus, had a positive impact on the viral vector manufacturing market. According to the World Health Organization Global COVID-19 Vaccination - Strategic Vision for 2022, there were at least 17 vaccines in use. As of September 2021, about 5.4 billion doses were administered worldwide, with another 300 and more vaccine candidates in clinical and preclinical development. As of January 2022, 2 viral vector vaccines had been authorized for emergency use in many countries for COVID-19 vaccine according to the Viral Vector Vaccines section by the Infectious Diseases Society of America. For instance, in April 2020, AstraZeneca and Oxford University announced their partnership to develop a viral vectored vaccine utilizing a modified replication-deficient chimp adenovirus vector, ChAdOx1. Also, Janssen Biotech (Johnson & Johnson) has developed a viral vector vaccine utilizing a replication-incompetent human adenovirus vector and received approval from Food and Drug Administration (FDA) in February 2021. The importance of viral vector manufacturing has increased manifold owing to the increase in research and developments due to the pandemic, which has greatly attributed to propelling the growth of the market.

Market Segmentation

• By Type

Retroviral vectors

Lentiviral Vectors

Adenoviral Vectors

Others

• By Application

Vaccinology

Gene Therapy

• By End-User

Pharmaceutical & Biotechnology Companies

Research Institutes

Contract Research Organizations

• By Geography

North America

• United States
• Canada
• Mexico

South America

• Brazil
• Argentina
• Others

Europe

• United Kingdom
• Germany
• France
• Spain
• Others

The Middle East and Africa

• UAE
• Saudi Arabia
• Others

Asia Pacific

• China
• India
• Japan
• South Korea
• Thailand
• Indonesia
• Taiwan
• Others